Abbott Laboratories stock traded at EUR 88.67 in after-hours trading on September 29, 2026, representing a minor decline of 0.11 percent against the prior session's close of EUR 88.77. The reference price for the day was established at EUR 88.77, with current market quotes showing a bid of EUR 88.54 and an ask of EUR 88.80 on the Xetra exchange.
Earlier in the week, on September 27, Abbott announced significant positive data from clinical studies regarding its continuous glucose monitoring (CGM) technology for adults with Type 2 diabetes using basal insulin. The research involving nearly 28,000 participants indicated that CGM use was associated with a 45 percent lower risk of death at 12 months and a 36 percent lower risk at 24 months.
Additionally, a separate French observational study covering more than 253,000 people found that hospitalizations for acute diabetes events fell by 47 percent among users of Abbott's Libre technology who were on basal insulin. These findings highlight the clinical efficacy and potential market value of the company's core diabetes management solutions.
On September 17, Abbott's board declared a quarterly common dividend of 63 cents per share, payable to shareholders of record as of October 15, 2026, with payment scheduled for November 16. This dividend declaration reinforces the company's commitment to returning capital to investors while maintaining its focus on high-impact medical technologies.
📉 Abbott stock closed at EUR 88.67, down 0.11% in after-hours trading on Sept 29, 2026.
🔬 New study shows Abbott's CGM reduces mortality risk by 45% for Type 2 diabetes patients.
🏥 French study links Abbott Libre technology to a 47% drop in acute diabetes hospitalizations.
💰 Board declared quarterly dividend of 63 cents per share, payable Nov 16 to record holders.
📉 Abbott stock closed at EUR 88.67 in after-hours trading on September 29, 2026, down 0.11 percent from the prior session's close of EUR 88.77.
🔬 New study data released on September 27 shows continuous glucose monitoring reduces mortality risk by 45% at 12 months for adults with Type 2 diabetes on basal insulin.
🏥 A separate French observational study involving over 253,000 people found a 47% reduction in hospitalizations for acute diabetes events among users of Abbott's Libre technology.
💰 The board declared a quarterly common dividend of 63 cents per share on September 17, payable November 16 to shareholders of record on October 15.
📊 Current market quotes show a bid of EUR 88.54 and an ask of EUR 88.80 following the Xetra close.
Bullish Signals
CGM linked to 45% lower death risk in 28k adults.
Hospitalizations fell 47% for 253k users of Libre tech.
Declared quarterly dividend of 63 cents per share.
Risk Factors
Stock down 0.11% after-hours on Sept 29, 2026.
Closing price EUR 88.67 vs prior session EUR 88.77.
Bullish Signals
Abbott announced data from studies showing continuous glucose monitoring is associated with a 45 percent lower risk of death at 12 months among nearly 28,000 adults with Type 2 diabetes using basal insulin.
A separate French observational study involving more than 253,000 people found that hospitalizations for acute diabetes events fell 47 percent among users of Abbott's Libre technology on basal insulin.
The company declared a quarterly common dividend of 63 cents per share, payable November 16, 2026, to shareholders of record at the close of business on October 15.
Risk Factors
Abbott stock traded down 0.11 percent in after-hours trading on September 29, 2026, closing at EUR 88.67 versus a prior session close of EUR 88.77.
The reference price for the session was EUR 88.77, with current quotes showing a bid of EUR 88.54 and an ask of EUR 88.80.
Abbott Laboratories (NYSE:ABT) reported strong second-quarter results with total sales increasing 13% to $12.59 billion and adjusted EPS rising 4% to $1.31. The company's Medical Devices segment, its largest business, grew 8.4% on a comparable basis, driven by double-digit growth in Electrophysiology and Rhythm Management. Additionally, the acquisition of Exact Sciences has successfully integrated into the portfolio, with Diagnostics sales surging 42.3% to $3.09 billion, largely fueled by growth in Cancer Diagnostics.
Abbott continues its robust track record as a dividend aristocrat, having increased its quarterly dividend for 54 consecutive years. For fiscal year 2026, the company raised its quarterly dividend by 6.8% to $0.63 per share and upgraded its full-year adjusted EPS guidance to a range of $5.45-$5.60. Management maintains a comparable sales growth outlook of 6.5%-7.5%, anticipating acceleration in the second half of the year despite some headwinds in Nutrition and Molecular Diagnostics segments.
The article contrasts Abbott's diversified profile with Gilead Sciences, noting that while Gilead shows stronger current momentum, it faces concentration risk from its HIV franchise which accounts for roughly three-quarters of product revenue. Abbott's strategy involves spreading risk across medical devices, diagnostics, nutrition, and pharmaceuticals, though it faces specific challenges such as lower respiratory-virus testing sales and higher intangible amortization costs following the Exact Sciences acquisition.
📈 Abbott Q2 sales rose 13% to $12.59B with comparable growth of 4.8%.
💊 Medical Devices grew 8.4% driven by strong Electrophysiology performance.
🔬 Diagnostics surged 42.3% due to Exact Sciences integration and cancer diagnostics.
💰 Dividend raised to $0.63/share for 2026, marking 54th consecutive increase.
⚠️ Nutrition sales fell 3.6% while Intangible amortization rose to $658M.
📈 Abbott Laboratories reported second-quarter sales of $12.59 billion, representing a 13% increase on a reported basis and a 4.8% comparable rise.
💊 The Medical Devices segment generated $5.85 billion in sales, growing 8.4% on a comparable basis with strong performance in Electrophysiology.
🔬 Diagnostics sales reached $3.09 billion, surging 42.3% on a reported basis driven by the integration of Exact Sciences and growth in Cancer Diagnostics.
💰 Abbott raised its quarterly dividend to $0.63 per share for 2026, marking its 54th consecutive year of dividend increases.
📈 Management upgraded full-year adjusted EPS guidance to $5.45-$5.60 while maintaining a comparable sales growth outlook of 6.5%-7.5%.
⚠️ Nutrition sales declined 3.6% on a comparable basis in the second quarter, contributing to uneven growth across the broad portfolio.
📉 Rapid and Molecular Diagnostics fell 8.0%, partly due to lower respiratory-virus testing sales volumes.
💸 Intangible amortization expenses increased to $658 million in Q2 following the Exact Sciences acquisition, impacting GAAP EPS.
🏥 The company expects sales and earnings growth to accelerate in the second half of the year to meet full-year targets.
🔍 Abbott offers a diversified risk profile compared to peers like Gilead, which relies heavily on its HIV franchise for revenue.
Bullish Signals
Sales grew 13% to $12.59B.
Medical Devices rose 8.4%.
Diagnostics surged 42.3% to $3.09B.
Dividend raised 6.8% to $0.63.
EPS guidance upgraded to $5.45-$5.60.
Risk Factors
Nutrition sales declined 3.6% on a comparable basis in Q2.
Bullish Signals
Abbott Laboratories reported strong second-quarter sales growth of 13% to $12.59 billion, demonstrating robust business momentum.
The Medical Devices segment grew 8.4% on a comparable basis, with specific double-digit growth in Electrophysiology and Rhythm Management areas.
Diagnostics sales surged 42.3% to $3.09 billion, driven by successful integration of Exact Sciences and growth in Cancer Diagnostics.
Abbott raised its quarterly dividend by 6.8% to $0.63 per share for 2026, extending its streak of 54 consecutive years of dividend increases.
The company upgraded its full-year adjusted EPS guidance to $5.45-$5.60, reflecting confidence in future performance.
Management maintains a comparable sales growth outlook of 6.5%-7.5%, anticipating acceleration in the second half of the year.
Risk Factors
Nutrition sales declined 3.6% on a comparable basis during fiscal Q2, highlighting uneven growth within the broad portfolio.
Abbott Laboratories stock declined 2.32% to close at USD 101.09 on September 24, 2026, trading below its yearly high despite recent positive earnings data. The company's market capitalization stood at approximately USD 174.9 billion with a daily trading volume of over 6 million shares.
Second-quarter financial results released earlier in July showed strong performance with EPS of USD 1.31, beating the consensus estimate of USD 1.28. Revenue reached USD 12.59 billion, representing a 13% increase from the year-earlier quarter and exceeding analyst expectations.
Management provided forward guidance for full-year 2026 EPS between USD 5.45 and USD 5.60, along with third-quarter earnings projections ranging from USD 1.38 to USD 1.46. Analyst sentiment remains bullish with an average 12-month target price of USD 120.26 supported by 22 buy ratings among 27 analysts.
The stock currently trades significantly below its 52-week high of USD 135.45, creating a potential upside opportunity relative to the consensus analyst target. The wide dispersion in individual analyst targets suggests varying expectations for future growth trajectories.
📉 Abbott stock fell 2.32% to close at USD 101.09 on September 24, 2026.
💰 Q2 EPS of USD 1.31 beat estimates by USD 0.03.
📈 Revenue reached USD 12.59 billion, a 13% increase from the prior quarter.
🎯 Full-year 2026 EPS guidance ranges from USD 5.45 to USD 5.60.
🔮 Third-quarter guidance projects EPS between USD 1.38 and USD 1.46.
📉 Abbott Laboratories stock fell 2.32% to close at USD 101.09 on September 24, 2026.
💰 Q2 EPS of USD 1.31 exceeded the consensus estimate of USD 1.28 by USD 0.03.
📈 Revenue reached USD 12.59 billion, a 13% increase from the year-earlier quarter.
🎯 Full-year 2026 EPS guidance ranges from USD 5.45 to USD 5.60.
👥 Analyst consensus target price is USD 120.26 with 22 buy ratings out of 27 analysts.
📊 Market capitalization stands at approximately USD 174.9 billion as of late September.
📉 Stock trades USD 34.36 below its 52-week high of USD 135.45.
🔮 Third-quarter guidance projects EPS between USD 1.38 and USD 1.46.
Bullish Signals
Q2 EPS beat consensus by USD 0.03 at USD 1.31.
Risk Factors
Stock declined 2.32% to $101.09 on Sept 24, 2026.
Price trades below 52-week high of $135.45.
Bullish Signals
Abbott Laboratories reported Q2 EPS of USD 1.31, beating the consensus estimate of USD 1.28 by USD 0.03.
Revenue grew to USD 12.59 billion in the second quarter, representing a 13% increase from the year-earlier quarter.
The company provided full-year 2026 EPS guidance of USD 5.45 to USD 5.60, establishing a measurable earnings floor.
Third-quarter earnings guidance ranges from USD 1.38 to USD 1.46, indicating continued growth expectations.
Analyst consensus target price of USD 120.26 suggests significant upside potential from current trading levels.
Risk Factors
Stock price declined 2.32% on September 24, 2026, closing at USD 101.09 below the previous close.
Current share price of USD 101.09 trades significantly below the 52-week high of USD 135.45.
Abbott Laboratories reported strong second-quarter results for 2026, posting adjusted earnings per share of $1.31 against a consensus estimate of $1.28. The company's revenue reached $12.59 billion, representing a significant year-over-year increase of 13.0%. This performance highlights the resilience of Abbott's core business segments amidst broader market conditions.
Beyond the headline numbers, the report provided updated guidance for the full fiscal year 2026. The company raised its adjusted EPS outlook to a range of $5.45 to $5.60, expanding from the previous forecast of $5.38 to $5.58. Additionally, Abbott maintained its comparable sales growth guidance between 6.5% and 7.5%, signaling confidence in sustained demand for its medical devices and diagnostics.
Despite the operational success, the stock traded down slightly on September 23, 2026, closing at $103.53. This price action reflects a market weighing the positive earnings beat against the company's distance from its 52-week high of $136.83. The valuation debate is further complicated by a recent legal settlement regarding powdered infant formula claims.
Financially, Abbott reported GAAP diluted EPS of $0.53 and net income attributable to common shareholders of $928 million for the quarter. Operating margins stood at 13.0%, indicating healthy profitability. The market capitalization was approximately $179 billion as of late September 2026, underscoring Abbott's position as a major player in the healthcare sector.
📈 Abbott beat Q2 2026 EPS expectations with $1.31 vs $1.28 consensus.
💰 Revenue surged 13.0% YoY to $12.59 billion in the quarter.
🚀 Full-year 2026 adjusted EPS guidance raised to $5.45-$5.60 range.
⚖️ Settled infant formula claims for $385 million related to 2022 recall.
📈 Abbott Laboratories beat Q2 2026 adjusted EPS expectations with a result of $1.31 versus the $1.28 consensus.
💰 Revenue surged to $12.59 billion, marking a robust 13.0% year-over-year growth for the quarter.
🚀 The company raised its full-year 2026 adjusted EPS guidance range to $5.45-$5.60 from the prior $5.38-$5.58.
📉 Stock price dipped 0.20% to close at $103.53, trading below its 52-week high of $136.83.
⚖️ Abbott agreed to a $385 million settlement regarding claims related to its 2022 powdered infant formula recall.
📊 Operating margin remained stable at 13.0%, while GAAP diluted EPS was reported at $0.53.
🎯 Comparable sales growth guidance for 2026 was retained in the range of 6.5% to 7.5%.
Bullish Signals
Adjusted EPS beat consensus by $0.03 at $1.31.
Risk Factors
Stock closed down slightly at $103.53, well below 52-week high.
Faces $385M legal settlement over powdered infant formula claims.
Bullish Signals
Abbott Laboratories delivered a solid earnings beat with adjusted EPS of $1.31, exceeding analyst consensus by $0.03.
The company achieved impressive revenue growth of 13.0% year-over-year, reaching $12.59 billion in Q2 2026.
Abbott raised its full-year 2026 adjusted EPS guidance to $5.45-$5.60, indicating strong management confidence.
The company maintained its comparable sales growth guidance of 6.5%-7.5%, suggesting sustained market demand.
Risk Factors
Abbott stock traded down slightly on the day, closing at $103.53 while remaining significantly below its 52-week high.
The company faces a quantifiable legal overhang after agreeing to pay a $385 million settlement for powdered infant formula claims.
Abbott Laboratories achieved a significant regulatory milestone with the FDA granting De Novo authorization for its Libre Duo, becoming the first company to clear a wearable device capable of continuously monitoring both glucose and ketone levels. This innovation targets an existing ecosystem of over 8 million users and aims to provide early warnings for diabetic ketoacidosis, a critical safety feature that distinguishes it from competitors.
Despite this breakthrough, Abbott's stock has underperformed relative to rival Dexcom, which rallied 34% year-to-date while Abbott declined 11% over the same period. The company trades at a forward P/E of 21x with analysts targeting a price of $120.20, suggesting potential for re-rating if the new device drives substantial revenue growth and market share expansion.
CEO Robert Ford highlighted that reimbursement expansion is crucial for accelerating growth, noting that potential U.S. Type 2 coverage could reach approximately 10 million Medicare beneficiaries. However, the full commercial impact of Libre Duo depends on future integrations with insulin pumps from major partners like Tandem and Insulet, which are not yet live.
Investors should monitor the upcoming Q3 earnings report for adjusted EPS guidance between $1.38 and $1.46, as well as any announcements regarding broader CMS coverage for Type 2 diabetes. These events are expected to be key catalysts in converting Abbott's first-mover status into durable earnings power and validating its beaten-down valuation.
🏥 Abbott FDA cleared Libre Duo as first wearable monitoring glucose and ketones.
📉 Stock down 11.29% year-over-year trading at 21x forward P/E with $120.20 target.
💰 Q2 CGM sales hit $2.188 billion, up 9.5% comparable growth rate.
🤝 Pending insulin pump integrations critical for workflow adoption but not yet live.
📈 CEO expects reimbursement expansion to accelerate growth toward 10 million Medicare users.
🏥 Abbott received FDA De Novo authorization for the Libre Duo, becoming the first wearable cleared to continuously monitor both glucose and ketone levels.
📉 The stock has declined 11.29% over the past year, trading at a forward P/E of 21x against an analyst price target of $120.20.
👥 The new device targets an existing ecosystem of over 8 million users with plans for a U.S. launch later in 2026 for patients ages 2 and older.
🤝 Planned integrations with insulin pumps from Beta Bionics, Sequel, Insulet, Tandem, and MiniMed are critical for workflow adoption but are not yet live.
📈 CEO Robert Ford indicated that reimbursement expansion could drastically accelerate growth, with potential U.S. Type 2 coverage reaching around 10 million Medicare beneficiaries.
⚖️ Competitor Dexcom shares have rallied 34% year-to-date, creating a performance gap that Abbott aims to close through the Libre Duo launch.
📅 The company plans to provide adjusted EPS guidance of $1.38 to $1.46 in the upcoming Q3 earnings report.
🔬 Ketone detection capability allows for early warning of diabetic ketoacidosis, which can develop within hours, offering a genuine clinical distinction.
Bullish Signals
First FDA clearance for glucose/ketone wearable device.
Stock declined 11% while rival Dexcom rallied 34% year-to-date.
Tandem and Insulet pump integrations are not yet live.
Regulatory milestone requires successful commercial execution for revenue.
Bullish Signals
Abbott Laboratories secured the first FDA clearance for a wearable device that simultaneously tracks glucose and ketones, addressing a critical safety need for diabetic ketoacidosis prevention.
The company enters the market with an established ecosystem of over 8 million existing users, providing a strong foundation for rapid adoption of the new Libre Duo technology.
Q2 CGM sales demonstrated robust growth of 9.5% to reach $2.188 billion, indicating sustained demand in the continuous monitoring sector.
CEO Robert Ford highlighted that reimbursement expansion could drastically accelerate growth, with potential coverage reaching approximately 10 million Medicare beneficiaries.
Risk Factors
The stock has underperformed significantly compared to rival Dexcom, which rallied 34% year-to-date while Abbott declined 11% over the same period.
Planned integrations with insulin pumps from major partners like Tandem and Insulet are not yet live, limiting the device's current utility as a differentiator in clinical workflows.
The regulatory milestone precedes immediate revenue impact, requiring successful commercial execution and reimbursement approvals to realize full value.
Abbott Laboratories stock opened on September 22, 2026, following a close price of USD 102.61 on the NYSE on September 21, 2026. The shares gained 0.7 percent for the session and were up 14.1 percent over the preceding three months from a low of USD 89.90. While the broader S&P 500 index rose 1.4 percent on the same date, Abbott's performance reflected specific market dynamics rather than broad index outperformance.
Key financial and legal developments continue to define the company's immediate outlook. The firm has confirmed a quarterly dividend of USD 0.63 per share, payable to shareholders on November 16, 2026. Simultaneously, Abbott agreed to a significant civil settlement totaling USD 385 million related to allegations concerning contaminated infant formula produced at its facilities in Sturgis and Casa Grande.
The company faces ongoing scrutiny regarding the legal exposure associated with the infant formula contamination allegations. This settlement represents a material cash outflow that impacts the company's liquidity and earnings for the period. Investors are monitoring how this specific liability, combined with the dividend payout schedule, influences Abbott's balance sheet and future operational flexibility in the coming quarters.
📈 Abbott stock gained 0.7% to close at USD 102.61 on Sept 21, 2026.
📊 Shares rose 14.1% over the last three months from USD 89.90.
💰 Company confirmed a quarterly dividend of USD 0.63 per share.
⚖️ Abbott agreed to a USD 385 million settlement for contaminated formula.
⚠️ Infant formula contamination legal issues remain a primary investor focus.
📈 Abbott Laboratories stock closed at USD 102.61 on September 21, 2026, marking a 0.7 percent gain for the session.
📊 The shares have appreciated 14.1 percent over the last three months, rising from a price of USD 89.90 to the current level.
💰 Abbott confirmed a quarterly dividend of USD 0.63 per share with an ex-dividend date leading to payment on November 16, 2026.
⚖️ The company agreed to a USD 385 million civil settlement regarding allegations of contaminated infant formula from its Sturgis and Casa Grande plants.
🏭 Legal developments involving the infant formula contamination remain a primary focus for investors analyzing Abbott's September 22 trading session.
Bullish Signals
Stock gained 0.7% to close at USD 102.61 on Sept 21, 2026.
Shares rallied 14.1% over past three months showing positive momentum.
Risk Factors
Settled infant formula claims for USD 385 million.
Faces legal/reputational risks from facility contamination.
Bullish Signals
Abbott Laboratories stock gained 0.7 percent to close at USD 102.61 on September 21, 2026, demonstrating resilience despite broader market volatility.
The company's shares have rallied 14.1 percent over the past three months, indicating sustained investor interest and positive momentum in the stock price.
Risk Factors
Abbott Laboratories agreed to a USD 385 million civil settlement regarding contaminated infant formula allegations, representing a significant immediate financial liability.
The company faces ongoing legal exposure and reputational risk linked to contamination issues at its Sturgis and Casa Grande manufacturing facilities.
As of September 21, 2026, Abbott Laboratories (ABT) is trading at $102.38, which is below its 50-day moving average of $106.19 and the Wall Street consensus target of $120.00 set by 27 analysts. The stock exhibits an RSI of 23, indicating it is in oversold territory according to CleaRank Financial AI, which rates the stock a Buy with a fair value of $103.00.
Financially, Abbott Laboratories demonstrated strong operational execution in Q2 2026 by beating EPS estimates by 2.34%, reporting $1.31 per share against expectations of $1.28. This beat resulted in a 1.87% stock price increase. Additionally, the company reported 13% revenue growth, significantly outpacing the Healthcare sector median of 8.1%, which highlights its competitive positioning and market demand.
Despite positive earnings, insider activity shows a net seller position with $48.6 million in share sales versus only $4.4 million in purchases, potentially signaling a lack of confidence in near-term appreciation. Long-term simulations project ABT could reach approximately $141 by 2030 in the base case, though historical performance since 2016 has lagged behind the S&P 500 benchmark.
Analysts and technical indicators suggest potential for further price declines before a significant recovery due to the stock trading below key moving averages. The article notes that while the company shows operational strength, the insider selling and technical oversold conditions present mixed signals for immediate investment strategy.
📈 Abbott beat Q2 EPS estimates by 2.34% with $1.31 per share.
📈 Revenue grew 13%, outpacing the Healthcare sector median of 8.1%.
📉 Insiders sold $48.6M in shares versus only $4.4M in purchases.
📉 Stock trades below 50-day and 200-day moving averages at oversold RSI 23.
🎯 Analyst consensus target price is $120.00 with a Buy rating.
📈 Abbott Laboratories beat Q2 2026 EPS estimates by 2.34%, reporting $1.31 per share versus the $1.28 consensus, leading to a 1.87% stock price increase.
📈 The company reported 13% revenue growth in Q2 2026, significantly outpacing the Healthcare sector median of 8.1% and highlighting strong competitive positioning.
📉 Insiders have sold $48.6 million worth of shares versus $4.4 million in purchases, indicating a net seller position that could signal a lack of confidence in near-term stock appreciation.
📉 The stock is trading below its 50-day moving average of $106.19 and 200-day moving average of $105.08, exhibiting an oversold RSI of 23.
🎯 Wall Street's consensus target price for ABT is $120.00 across 27 analysts, while CleaRank Financial AI rates it a Buy with a fair value of $103.00.
📉 Historical data shows a $10,000 investment in ABT in September 2016 would be worth about $24,478 today, compared to $35,293 for the S&P 500 benchmark.
🔮 CleaRank's Monte Carlo simulation projects a base case price near $141 for ABT by 2030, representing a 1.4x return over four years from current levels.
⚠️ The downside path in simulations ends near $76.04, assuming no dividends are reinvested and based on historical volatility and drift.
Bullish Signals
Beat Q2 EPS by 2.34% at $1.31 vs $1.28 consensus.
Revenue grew 13%, outpacing sector median of 8.1%.
Risk Factors
Insiders sold $48.6M vs $4.4M buys, signaling lack of confidence.
Stock trades below 50-day ($106.19) and 200-day ($105.08) averages.
Bullish Signals
Abbott Laboratories beat Q2 2026 EPS estimates by 2.34%, reporting $1.31 per share versus the $1.28 consensus, leading to a 1.87% stock price increase.
The company reported 13% revenue growth in Q2 2026, significantly outpacing the Healthcare sector median of 8.1%, highlighting strong competitive positioning and market demand.
Risk Factors
Insiders have sold $48.6 million worth of shares versus $4.4 million in purchases, indicating a net seller position that could signal a lack of confidence in near-term stock appreciation.
The stock is trading below its 50-day moving average of $106.19 and 200-day moving average of $105.08, exhibiting an oversold RSI of 23 which suggests potential for further price declines before recovery.
Abbott Laboratories stock gained value on September 19, 2026, trading at USD 102.35 following a significant reduction in legal uncertainty regarding its infant formula business. The company agreed to a settlement of nearly USD 385 million related to a 2022 recall and plant shutdown, resolving broad federal and state claims without admitting liability. This financial clean-up effectively removes a major overhang from the stock's valuation.
Financial performance for the quarter ended June 2026 was robust, with revenue reaching USD 12.59 billion, representing a 13.0 percent year-over-year increase. Adjusted earnings per share grew to USD 1.31, surpassing analyst consensus estimates despite ongoing litigation costs. Management maintained full-year 2026 guidance of USD 5.45 to USD 5.60 in adjusted EPS, signaling confidence in earnings resilience.
Analyst sentiment remains broadly positive, with a Wall Street average price target of USD 119.50 above the current share price. Recent upgrades from BTIG Research and Wolfe Research reinforce this bullish stance. While investors monitor risks such as margin compression and the financial impact of the settlement, product developments like the TactiFlex Duo ablation catheter offer long-term growth potential in the cardiovascular portfolio.
The company is positioned for continued scrutiny ahead of its next earnings report scheduled for October 16, 2026. With a market capitalization of USD 177.11 billion, Abbott balances the immediate financial impact of the settlement against its strong operational growth and strategic product approvals, maintaining a solid investment case within its current trading range.
📈 Abbott stock trades at $102.35 with bullish analyst price targets near $119.50.
💰 June revenue hit $12.59 billion, up 13%, while adjusted EPS beat consensus.
⚖️ Legal risk reduced after settling infant formula claims for nearly $385 million total.
🔬 TactiFlex Duo catheter approval expands cardiovascular portfolio and supports long-term growth.
📅 Next earnings report scheduled for October 16, 2026, as a key checkpoint.
📈 Abbott Laboratories stock traded at USD 102.35 on September 19, 2026, supported by reduced legal risk from a nearly USD 385 million infant formula settlement.
💰 The company reported June-quarter revenue of USD 12.59 billion, up 13.0 percent year over year, with adjusted EPS of USD 1.31 beating consensus.
🤝 Abbott agreed to pay about USD 348.7 million to the federal government and more than USD 35 million to states to resolve claims over powdered infant formula manufacturing issues.
📊 Wall Street's average price target stands at USD 119.50, above the latest quoted share price, indicating a bullish analyst stance.
🚀 Regulatory approval for the TactiFlex Duo ablation catheter adds to Abbott's cardiovascular portfolio and could support long-term revenue growth.
📅 The next scheduled earnings report is expected on October 16, 2026, serving as a key checkpoint for investors.
🏛️ New York alone is expected to receive more than USD 9.3 million from the settlement proceeds, with around USD 5.3 million earmarked for Medicaid.
📉 Profit margin for 2026 is projected at roughly 11.64 percent, with investors monitoring potential compression risks alongside the settlement impact.
🔍 The settlement resolves a broad set of federal and state claims, closing key investigations into manufacturing issues without an admission of liability.
Bullish Signals
Legal settlement reduced uncertainty by USD 385 million.
Risk Factors
2026 profit margin projected at roughly 11.64 percent.
USD 385 million infant formula settlement weighs on earnings.
Must balance growth with financial clean-up from settlement.
Bullish Signals
Abbott Laboratories stock gained value as a nearly USD 385 million infant formula settlement reduced significant legal uncertainty and resolved broad federal and state claims.
The company delivered strong June-quarter revenue of USD 12.59 billion, representing a 13.0 percent year-over-year increase while beating EPS consensus estimates.
Management maintained full-year 2026 guidance of USD 5.45 to USD 5.60 in adjusted EPS, signaling confidence in earnings resilience despite litigation costs.
Wall Street's average price target stands at USD 119.50, above the current share price, with recent upgrades from BTIG Research and Wolfe Research reinforcing a bullish stance.
Regulatory approval for the TactiFlex Duo ablation catheter adds to Abbott's cardiovascular portfolio, offering potential for long-term revenue growth.
Risk Factors
Investors face risks including margin compression, with profit margin for 2026 projected at roughly 11.64 percent.
The financial impact of the roughly USD 385 million infant formula settlement weighs on earnings quality and represents a significant cash outflow.
While Wall Street remains largely bullish, the company must balance growth initiatives with the ongoing financial clean-up from the infant formula episode.
Abbott Laboratories reported strong financial results for the June quarter, trading at USD 102.35 on September 19, 2026. The company posted earnings per share of USD 1.31, which beat analyst estimates by USD 0.03. Revenue reached USD 12.59 billion, representing a significant year-over-year increase of 13.0 percent.
Looking ahead, Abbott provided guidance for the third quarter of 2026 with EPS expected between USD 1.38 and USD 1.46. The full-year fiscal 2026 outlook was set at USD 5.45 to USD 5.60 per share. This forward-looking guidance positions the company's annual earnings expectations above the current analyst consensus of USD 5.52.
Wall Street analysts have responded positively to the results, with BTIG Research raising its price target to USD 134 and Wolfe Research lifting Abbott to an outperform rating with a USD 130 target. Despite these upgrades, the current share price remains below the consensus target of USD 119.50, suggesting potential upside for investors.
Abbott Laboratories operates within the Health Care Equipment & Supplies sector with a market capitalization of USD 177.11 billion. The stock has a 52-week trading range between USD 81.97 and USD 137.49, indicating volatility but maintaining a position well above its yearly low following the recent earnings beat.
📈 Abbott June EPS beat estimates by USD 0.03 at USD 1.31.
💰 Revenue surged 13.0% year-over-year to USD 12.59 billion.
🔮 Q3 2026 guidance set between USD 1.38 and USD 1.46 per share.
🚀 BTIG raised price target to USD 134; Wolfe upgraded to outperform at USD 130.
💹 Market cap USD 177.11 billion; stock trades below consensus target of USD 119.50.
📈 Abbott Laboratories reported June-quarter EPS of USD 1.31, beating estimates by USD 0.03.
💰 Revenue surged to USD 12.59 billion, marking a 13.0 percent year-over-year growth.
🔮 Q3 2026 EPS guidance is set between USD 1.38 and USD 1.46.
📅 Full-year fiscal 2026 guidance ranges from USD 5.45 to USD 5.60 per share.
🚀 BTIG Research raised its price target to USD 134 following the earnings report.
⭐ Wolfe Research upgraded Abbott to outperform with a USD 130 price target.
💹 Market capitalization stands at USD 177.11 billion as of September 19, 2026.
📉 Current share price of USD 102.35 trades below the consensus target of USD 119.50.
📊 The stock is trading within a 52-week range of USD 81.97 to USD 137.49.
Bullish Signals
Beat Q2 EPS by $0.03 at $1.31.
Revenue grew 13% YoY to $12.59B.
FY26 EPS guidance: $5.45-$5.60.
BTIG target raised to $134.
Bullish Signals
Abbott Laboratories beat earnings expectations with June-quarter EPS of USD 1.31, surpassing analyst estimates by USD 0.03.
Revenue growth was robust at 13.0 percent year over year, reaching a total of USD 12.59 billion for the quarter.
The company provided optimistic full-year guidance with FY 2026 EPS expectations between USD 5.45 and USD 5.60.
Analyst sentiment is bullish, evidenced by BTIG Research raising its target to USD 134 and Wolfe Research upgrading the stock to outperform.
The full-year earnings outlook centers above the current analyst consensus of USD 5.52 EPS.
Abbott Laboratories (ABT) shares closed at $103.09, rising 1.12% to outperform the broader market despite a downturn in major indices like the S&P 500 and Nasdaq. However, the stock has underperformed over the past month, falling 8.36% compared to a smaller decline for the Medical sector and the S&P 500.
Investors are closely watching Abbott's upcoming earnings release, with consensus estimates projecting an EPS of $1.43, representing a 10% year-over-year increase. Revenue is expected to reach $12.91 billion, marking a significant 13.52% growth from the prior quarter.
Analyst sentiment remains cautiously optimistic, reflected in recent positive revisions to earnings estimates which typically correlate with share price momentum. Abbott currently trades at a Forward P/E of 18.46, offering a discount relative to its industry average of 20.16.
📈 Abbott shares rose 1.12% to $103.09, beating S&P 500.
📉 Stock fell 8.36% this month, lagging medical sector decline.
💰 Analysts expect EPS of $1.43 and revenue of $12.91B.
📊 Consensus projects annual earnings of $5.52 with 7.18% growth.
🔍 Positive analyst revisions signal optimism for Abbott's near-term trends.
📈 Abbott (ABT) shares closed up 1.12% at $103.09, outpacing the S&P 500's daily loss.
📉 The stock has fallen 8.36% over the past month, lagging the Medical sector's decline.
💰 Analysts expect Abbott to report EPS of $1.43 and revenue of $12.91 billion in the upcoming quarter.
📊 Consensus estimates project annual earnings of $5.52 per share with 7.18% growth.
🔍 Recent positive analyst estimate revisions signal optimism regarding Abbott's near-term business trends.
💵 Abbott trades at a Forward P/E of 18.46, which is below the industry average of 20.16.
📉 The company holds a Zacks Rank of #3 (Hold) with a PEG ratio of 1.89.
Bullish Signals
Shares rose 1.12% to $103.09, outperforming S&P 500.
EPS expected up 10% YoY to $1.43.
Revenue forecast grows 13.52% sequentially to $12.91B.
Analyst revisions show growing confidence in profitability.
Trades at Forward P/E of 18.46 vs 20.16.
Risk Factors
Stock declined 8.36%, underperforming Medical sector's 2.01% loss.
Abbott Laboratories (NYSE: ABT) is trading at a forward P/E of 17x, significantly below its $137.49 52-week high and the $116.54 analyst consensus target, despite posting four consecutive EPS beats. The market continues to price the stock as a slow-and-steady dividend stalwart with a beta of 0.607, but management argues this framing undervalues the company's strategic transformation into a growth-oriented compounder.
The company is pivoting toward high-growth medical devices, where the FreeStyle Libre continuous glucose monitor franchise generated $2.08 billion in Q1 2026, up 13.8%. CEO Robert Ford highlights a massive runway for the global CGM market, projecting growth from 12 million to 80 million users, while established pharmaceuticals and international sales also posted double-digit growth of 13.2% and 11.3% respectively.
A major catalyst is the $21 billion acquisition of Exact Sciences, which closed on March 23, 2026, adding Cologuard cancer diagnostics to the portfolio. Management expects this unit to generate approximately $3 billion in incremental sales for 2026, driven by high sensitivity and convenience that addresses a screening gap among 50 million Americans.
📉 Abbott trades at 17x forward earnings despite a 28.8% year-to-date decline.
💊 Dividend Aristocrat with 54 consecutive years of increases and $0.63 quarterly payout.
🩸 Medical Devices drove Q1 growth to $5.54 billion, up 13.2%.
📱 FreeStyle Libre CGM revenue hit $2.08 billion as market approaches 80 million users.
🧬 Closed $21 billion Exact Sciences acquisition to launch new Cancer Diagnostics unit.
📉 Abbott trades at 17x forward earnings with shares down 28.8% year-to-date, yet the stock has posted four consecutive EPS beats.
💊 The company is a Dividend Aristocrat with a 54th consecutive year of dividend increases and a quarterly payout of $0.63 per share.
🩸 Medical Devices became the dominant engine, generating $5.54 billion in Q1 2026, up 13.2% from the prior period.
📱 The FreeStyle Libre CGM franchise cleared $2.08 billion in Q1 2026, growing 13.8% as the market expands toward 80 million users.
🧬 Abbott closed its $21 billion acquisition of Exact Sciences on March 23, 2026, launching a new Cancer Diagnostics unit.
🛡️ The Cologuard cancer test is expected to generate roughly $3 billion in incremental sales for 2026 with 95% sensitivity.
💰 Established Pharmaceuticals grew 13.2% while international sales rose 11.3% in the first quarter of 2026.
📉 Nutrition revenue fell 6.0% to $2.02 billion as management deliberately focused on products with positive volume responses to price reductions.
⚠️ Challenges include competition from DexCom, China volume-based procurement, and $0.20 per share of Exact Sciences dilution.
Bullish Signals
Four EPS beats; Q1 2026 adjusted EPS $1.15.
FreeStyle Libre CGM revenue $2.08B, up 13.8%.
Medical Devices revenue $5.54B, up 13.2%.
Exact Sciences deal adds ~$3B incremental sales.
Dividend Aristocrat; 54th year of increases.
Risk Factors
Nutrition revenue fell 6.0% to $2.02B in Q1 2026.
Shares down 28.8% YTD, trading below $116.54 target.
Bullish Signals
Abbott posted four consecutive EPS beats with adjusted Q1 2026 EPS at $1.15, exceeding market expectations.
The FreeStyle Libre CGM franchise generated $2.08 billion in Q1 2026, growing 13.8% as the global market expands significantly.
Medical Devices revenue surged to $5.54 billion in Q1 2026, up 13.2%, establishing it as the company's dominant growth engine.
The $21 billion Exact Sciences acquisition is expected to contribute approximately $3 billion in incremental sales for 2026.
Established Pharmaceuticals grew 13.2% and international sales rose 11.3%, demonstrating resilience across key segments.
Abbott maintains a 54th consecutive year of dividend increases, reinforcing its status as a Dividend Aristocrat with a $0.63 quarterly payout.
Risk Factors
Nutrition revenue declined 6.0% to $2.02 billion in Q1 2026 as the company pivots away from legacy baby formula and branded generics.
Shares are down 28.8% year-to-date and 32.1% over one year, trading well below the analyst consensus buy target of $116.54.
Abbott Laboratories received FDA De Novo authorization for the Libre Duo, becoming the first company with a wearable device capable of continuously monitoring both glucose and ketone levels. This regulatory milestone targets an existing ecosystem of over 8 million users and aims to detect rising ketones that can precede diabetic ketoacidosis within hours, offering a genuine clinical distinction in diabetes care.
Despite this breakthrough, Abbott's stock has declined 11% over the past year, trading at a forward P/E of 21x against an analyst target of $120.20. The company raised its full-year adjusted EPS guidance to between $5.45 and $5.60, while Q2 continuous glucose monitoring (CGM) sales reached $2.188 billion, growing 9.5% on a comparable basis. CEO Robert Ford emphasized that reimbursement expansion is critical for accelerating growth.
The commercial success of the Libre Duo hinges on future integrations with insulin pumps from major partners like Tandem and Insulet, which are not yet live in the U.S. Additionally, potential coverage for around 10 million Medicare beneficiaries could significantly impact adoption. Analysts view the authorization as meaningful but insufficient alone to warrant a stock re-rating until pump partners ship integrated systems and CMS moves on broader Type 2 coverage.
🏥 Abbott becomes first wearable cleared to monitor glucose and detect ketones.
🤝 Pump integrations with Tandem and Insulet are critical for Libre Duo adoption.
⚠️ Stock remains undervalued until partners ship integrated systems for re-rating.
📈 Reimbursement expansion could reach 10 million Medicare beneficiaries by 2026.
🏥 Abbott Laboratories secured FDA De Novo authorization for the Libre Duo, becoming the first wearable cleared to continuously monitor glucose and detect ketones.
📉 The stock has fallen 11% year-over-year despite a recent 9.2% rally, currently trading at $114.10 with an analyst price target of $120.20.
💰 Q2 CGM sales reached $2.188 billion, representing a 9.5% comparable growth rate as the company defends against deceleration narratives.
🤝 Planned integrations with insulin pumps from partners like Tandem and Insulet are identified as the commercial hinge for Libre Duo's adoption.
👥 The device targets an existing ecosystem of over 8 million users, with a planned U.S. launch later in 2026 for patients ages 2 and older.
📈 CEO Robert Ford highlighted that reimbursement expansion could drastically accelerate growth, potentially reaching around 10 million Medicare beneficiaries.
⚠️ Analysts caution that the regulatory win is insufficient on its own to warrant a stock re-rating until pump partners ship integrated systems.
🔍 The FDA authorization confirms Abbott's timeline for U.S. discussions which were previously described as being in very advanced final stages.
Bullish Signals
FDA cleared Libre Duo as only dual-monitor wearable.
Q2 CGM sales hit $2.188B, up 9.5%.
Raised full-year EPS guidance to $5.45-$5.60.
Targets 8M+ users with new Libre Duo device.
Risk Factors
Stock down 11% YTD amid valuation skepticism.
Insulin pump integrations not yet live in U.S.
FDA approval insufficient without reimbursement news.
Bullish Signals
Abbott Laboratories achieved a regulatory first with the FDA De Novo authorization for the Libre Duo, becoming the only company with a wearable cleared to continuously monitor both glucose and ketones.
The company reported strong Q2 CGM sales of $2.188 billion, growing 9.5% on a comparable basis, demonstrating resilience in its core diabetes business.
Abbott raised its full-year adjusted EPS guidance to a range of $5.45 to $5.60, signaling confidence in future earnings performance.
The Libre Duo targets an established ecosystem of over 8 million users, providing a substantial existing customer base for the new device.
Risk Factors
Abbott's stock has declined 11% over the past year and 7.25% year-to-date, indicating market skepticism regarding its current valuation despite recent regulatory wins.
Planned integrations with insulin pumps from key partners like Tandem and Insulet are not yet live in the U.S., limiting the immediate workflow impact of the Libre Duo.
Analysts view the FDA authorization as insufficient on its own to warrant a stock re-rating until reimbursement announcements and pump partner shipments occur.
Abbott Laboratories reported a strong second quarter ended July 16, 2026, with revenue reaching $12.59 billion, representing a 13.0 percent year-over-year increase. The company delivered adjusted earnings per share of $1.31, which beat the consensus estimate of $1.28 by $0.03. This performance was driven by its diversified product mix spanning diagnostics, medical devices, nutrition, and established pharmaceuticals.
Following the quarterly results, management provided forward guidance for the third quarter of 2026 with EPS expected between $1.38 and $1.46, and full-year fiscal 2026 EPS guidance ranging from $5.45 to $5.60. The company maintained a net margin of 11.65 percent and a return on equity of 17.69 percent during the period. Analysts maintain a consensus target price of $119.50, suggesting potential upside for the stock currently trading near $108.
Financial metrics indicate robust operational health with free cash flow reported at $916.0 million in the first quarter of 2026, though this figure saw a slight decline of 1.8 percent compared to the same quarter a year prior. The market capitalization stands at approximately $187.38 billion as of September 4, 2026, with shares trading below their 52-week high and the consensus analyst target price.
📈 Abbott Q2 revenue rose 13% to $12.59 billion.
💰 Adjusted EPS of $1.31 beat analyst estimates by $0.03.
🎯 Full-year fiscal 2026 EPS guidance raised to $5.45-$5.60.
📉 Stock trades near $108.29, below $119.50 consensus target.
📅 Q3 2026 EPS guidance set between $1.38 and $1.46.
📈 Abbott Laboratories reported Q2 revenue of $12.59 billion, marking a 13.0 percent increase from the prior year.
💰 The company delivered adjusted EPS of $1.31, beating analyst consensus estimates by $0.03.
🎯 Management raised full-year fiscal 2026 EPS guidance to a range of $5.45 to $5.60.
📊 Net margin for the quarter stood at 11.65 percent with a return on equity of 17.69 percent.
💵 Free cash flow for Q1 2026 was reported at $916.0 million, down 1.8 percent year-over-year.
📉 Stock price traded near $108.29, trading below the consensus analyst target of $119.50.
🏥 Business segments include diagnostics, medical devices, nutrition, and established pharmaceuticals.
📅 Q3 2026 EPS guidance is set between $1.38 and $1.46 per share.
Bullish Signals
Abbott Laboratories beat Q2 consensus EPS estimates by $0.03, delivering $1.31 adjusted earnings versus the expected $1.28.
The company achieved a 13.0 percent year-over-year revenue growth, reaching $12.59 billion in total revenue for the quarter.
Management provided strong full-year fiscal 2026 guidance with EPS projected between $5.45 and $5.60.
Abbott maintained healthy profitability metrics with a net margin of 11.65 percent and a return on equity of 17.69 percent.
Analyst consensus target price of $119.50 implies approximately 10.4 percent upside from the current trading price.
Risk Factors
Free cash flow for Q1 2026 declined by 1.8 percent year-over-year to $916.0 million.
Shares traded below their 52-week high range, indicating some near-term price weakness relative to recent peaks.
The article highlights Mereo BioPharma Group (MREO) as a potential growth stock capable of delivering significant returns, noting that its American depository shares have lost approximately 65% of their value since April 2019 due to market impatience with clinical-stage biotechs. The primary catalyst for Mereo is its anti-TIGIT therapy candidate, etigilimab, which is currently in a combined phase 1/2 basket study evaluating its utility in combination with Bristol Myers Squibb's checkpoint inhibitor Opdivo for various solid tumors. Top-line data from this trial is expected in approximately 18 months, but the company plans to provide multiple interim updates that could serve as major share price catalysts. Mereo maintains a cash runway extending into 2024, reducing the immediate need to raise capital, though management has expressed a desire to partner with larger biopharmaceutical firms, potentially leading to a high-dollar licensing agreement or buyout within two years. The main downside risk involves the high failure rate of early-stage cancer therapies in clinical trials, which could weigh heavily on the stock if etigilimab does not succeed.
Senseonics Holdings (SENS) is presented as another aggressive growth opportunity centered on its implantable continuous glucose monitoring (CGM) device franchise, Eversense. The company aims to improve its competitive positioning against market leaders like DexCom and Abbott Laboratories by seeking FDA approval for an 180-day version of the Eversense CGM system, a regulatory application submitted over a year ago that could be decided soon. Senseonics projects that this approval would drive top-line growth at a compound annual rate of over 70% over the next five years, transforming the current 90-day device into a more competitive product in the U.S. market. While the CGM market has grown by over 10% annually for the past five years and is forecast to continue growing, Senseonics faces significant risks from competing against well-capitalized medical-device giants with superior resources, which could dampen sales even if regulatory approval is granted.
The analysis concludes that both Mereo BioPharma Group and Senseonics Holdings represent low-priced healthcare stocks with the potential for 1,000%-plus returns within two to three years, provided their key development milestones are met. For Mereo, success hinges on the performance of etigilimab in combination with Bristol Myers Squibb's Opdivo and potential strategic partnerships, while investors are advised to keep positions small due to the binary nature of clinical trial outcomes. For Senseonics, the inflection point is the FDA decision on the longer-lasting Eversense device, which could unlock substantial growth if it successfully challenges established competitors like DexCom and Abbott Laboratories. Both companies are characterized as suitable for ultra-aggressive investors willing to tolerate high volatility in exchange for the possibility of a monstrous run higher driven by specific regulatory or clinical data events.
📉 ABT faces downside risk if its etigilimab therapy fails in clinical trials.
💊 ABT's primary catalyst is anti-TIGIT therapy etigilimab combined with Bristol Myers Squibb's Opdivo.
📅 ABT expects top-line data from the etigilimab trial in approximately 18 months.
💰 ABT has cash runway extending into 2024, reducing immediate capital raise needs.
🤝 ABT management seeks partnerships for a potential high-dollar licensing or buyout within two years.
📉 Mereo BioPharma Group (MREO) shares have declined approximately 65% since April 2019 due to market impatience with clinical-stage biotechs.
💊 The company's primary growth catalyst is its anti-TIGIT therapy, etigilimab, which is currently in a combined phase 1/2 basket study evaluating combination treatment with Bristol Myers Squibb's Opdivo.
📅 Mereo is expected to release top-line data from the etigilimab trial in approximately 18 months, pending multiple interim progress updates that could act as share price catalysts.
💰 Mereo's cash runway extends into 2024, reducing the immediate need for the company to raise capital from public markets over the next year and a half.
🤝 Management has expressed a desire to partner with larger biopharmaceutical companies, potentially leading to a high-dollar licensing agreement or buyout for etigilimab within two years.
⚠️ Investors face downside risk as early-stage cancer therapies frequently fail in clinical trials, which could heavily weigh on Mereo's share price if etigilimab does not succeed.
🩺 Senseonics Holdings (SENS) offers an implantable continuous glucose monitoring device franchise called Eversense that targets a market growing at over 10% annually.
⏳ The company is awaiting a potential FDA regulatory approval for its 180-day version of the Eversense CGM system, which was submitted over a year ago.
📈 If approved, Senseonics projects top-line revenue growth exceeding 70% compound annual growth rate over the next five years due to the longer-lasting device.
🏆 The proposed 180-day Eversense device aims to improve competitive positioning against market leaders DexCom and Abbott Laboratories in the U.S. market.
⚔️ Senseonics faces competition from well-capitalized medical-device giants, creating a risk that FDA approval may not result in a parabolic rise in sales.
🎯 Both Mereo and Senseonics are highlighted as low-priced healthcare stocks with potential to generate 1,000% or more returns within the next two to three years for aggressive investors.
First Nebraska Trust Co acquired a new position in Abbott Laboratories (NYSE:ABT) during the first quarter, purchasing 5,959 shares valued at approximately $612,000. Several other hedge funds, including MidAtlantic Capital Management Inc., Cornerstone Financial Management LLC, and Purpose Unlimited Inc., also established or modified new stakes in the company during the fourth quarter, with individual investments ranging from roughly $25,000 to $26,000.
Abbott Laboratories recently reported strong financial results for the quarter ending July 16th, posting earnings per share of $1.31 which exceeded analyst consensus estimates of $1.28. The company generated revenue of $12.59 billion, surpassing expectations of $12.52 billion, and achieved a net margin of 11.65% with revenue growing 13.0% year-over-year. Institutional ownership stands at 75.18%, reflecting significant interest from the investment community.
The healthcare giant provided forward-looking guidance for Q3 2026 EPS between $1.38 and $1.46, and full-year 2026 EPS between $5.45 and $5.60, slightly below the average analyst prediction of $5.52. The company also announced a quarterly dividend of $0.63 per share payable on August 17th to shareholders of record as of July 15th, representing an annualized yield of 2.4% and a payout ratio of 81.55%.
📈 First Nebraska Trust Co bought $612,000 Abbott stock in Q1.
🏦 Hedge funds added $25k-$26k stakes in Q4.
💰 Q3 EPS hit $1.31, beating estimates by $0.03.
📊 Revenue reached $12.59 billion, up 13% year-over-year.
📅 2026 EPS guidance ranges from $1.38 to $1.46.
📈 First Nebraska Trust Co purchased a new position in Abbott Laboratories valued at approximately $612,000 during the first quarter.
🏦 Multiple hedge funds including MidAtlantic Capital Management Inc. and Cornerstone Financial Management LLC added new stakes worth roughly $25,000 to $26,000 each in the fourth quarter.
💰 Abbott Laboratories reported quarterly EPS of $1.31, beating analyst consensus estimates of $1.28 by $0.03.
📊 Revenue reached $12.59 billion for the quarter, exceeding expectations of $12.52 billion and growing 13.0% year-over-year.
📉 The stock trades at a PE ratio of 34.30 with a market capitalization of $183.40 billion.
📅 Q3 2026 EPS guidance is set between $1.38 and $1.46, while full-year 2026 guidance ranges from $5.45 to $5.60.
💸 A quarterly dividend of $0.63 per share will be paid on August 17th with an ex-dividend date of July 15th.
📈 The annualized dividend yield is 2.4% based on a payout ratio of 81.55%.
🏢 Institutional investors own 75.18% of the company's outstanding shares.
🔬 Abbott operates through diagnostics, medical devices, nutritionals, and established pharmaceuticals business areas.
Bullish Signals
EPS beat at $1.31 vs $1.28 consensus.
Revenue exceeded estimates at $12.59 billion.
Net margin reached 11.65% with ROE of 17.69%.
Revenue grew 13.0% year-over-year.
Hedge funds initiated new positions in Q1 and Q4.
Bullish Signals
Abbott Laboratories beat quarterly earnings expectations with EPS of $1.31 versus a consensus of $1.28.
Revenue of $12.59 billion exceeded analyst estimates of $12.52 billion, demonstrating strong top-line performance.
The company achieved a net margin of 11.65% and a return on equity of 17.69%, indicating healthy profitability.
Revenue grew by 13.0% year-over-year, signaling robust business expansion.
Multiple hedge funds initiated new positions in the stock during the first and fourth quarters.
First Nebraska Trust Co invested approximately $612,000 in a new position, indicating significant institutional confidence.
The company maintains a solid balance sheet with a current ratio of 1.38 and a debt-to-equity ratio of 0.57.
Equities analysts have issued mixed but generally positive signals regarding Abbott Laboratories (NYSE:ABT) ahead of its FY2027 earnings. Erste Group Bank lifted its full-year EPS estimate to $6.06, while JPMorgan Chase raised its price target to $120 and maintained an 'overweight' rating. Conversely, Bank of America cut its target to $102, and Daiwa Securities lowered its rating to neutral with a $92 target, reflecting varied market perspectives on the healthcare giant's valuation.
The company recently reported strong quarterly results for the quarter ended July 16th, beating analyst expectations. Abbott Laboratories posted earnings per share of $1.31 compared to a consensus of $1.28, with revenue reaching $12.59 billion, a 13% year-over-year increase. The firm also provided forward guidance for Q3 2026 EPS between $1.38 and $1.46, and set full-year FY 2026 EPS targets ranging from $5.45 to $5.60.
Abbott Laboratories continues to offer attractive income characteristics with a declared quarterly dividend of $0.63 per share, payable on August 17th to shareholders of record as of July 15th. This represents an annualized dividend yield of 2.4% and a payout ratio of 81.55%. Institutional ownership remains high at 75.18%, with significant recent position increases from major hedge funds like J. Stern & Co., Norges Bank, and Arrowstreet Capital.
📈 FY2027 EPS estimate raised to $6.06 by Erste Group Bank.
📉 Bank of America cut price target from $120 to $102.
🚀 JPMorgan Chase lifted target to $120 and reaffirmed overweight rating.
💰 Q2 EPS beat at $1.31 with revenue growth of 13%.
🎯 FY2026 guidance set between $5.45 and $5.60 per share.
📈 Erste Group Bank raised its FY2027 EPS estimate for Abbott Laboratories to $6.06 per share.
📉 Bank of America reduced its price target from $120.00 to $102.00 in a recent research report.
🚀 JPMorgan Chase lifted its price target to $120.00 and reaffirmed an 'overweight' rating.
💰 Abbott Laboratories reported Q2 EPS of $1.31, beating the consensus estimate of $1.28.
📈 Revenue for the quarter reached $12.59 billion, representing a 13% year-over-year growth.
🎯 The company provided FY 2026 guidance with EPS targets between $5.45 and $5.60.
💸 A quarterly dividend of $0.63 per share was declared for payment on August 17th.
📊 Institutional investors own 75.18% of the company's outstanding shares.
🏦 J. Stern & Co. LLP increased its stake by over 12,400% in the fourth quarter.
🔍 The stock currently trades at a P/E ratio of 34.25 with a market cap of $183.12 billion.
Bullish Signals
Beat EPS expectations at $1.31 vs $1.28 consensus.
Revenue grew 13% year-over-year to $12.59 billion.
JPMorgan upgraded price target to $120 with 'overweight' rating.
Institutional investors significantly increased holdings in the stock.
Maintains 2.4% dividend yield with $2.52 annualized payout.
Risk Factors
Bank of America cut target to $102.00.
Daiwa downgraded to neutral at $92.00.
Bullish Signals
Abbott Laboratories beat quarterly earnings expectations, reporting $1.31 EPS versus the consensus of $1.28.
The company achieved strong revenue growth of 13% year-over-year, reaching $12.59 billion for the quarter.
JPMorgan Chase upgraded its price target to $120 and maintained an 'overweight' rating on the stock.
Erste Group Bank increased its FY2027 EPS forecast to $6.06, signaling confidence in future performance.
Major institutional investors like J. Stern & Co., Norges Bank, and Arrowstreet Capital significantly increased their holdings.
The company maintains a consistent dividend policy with a 2.4% yield and an annualized payout of $2.52 per share.
Risk Factors
Bank of America lowered its price target from $120.00 to $102.00, indicating some analysts see limited upside.
Daiwa Securities downgraded the stock from 'outperform' to 'neutral' with a lower price target of $92.00.
Abbott Laboratories (NYSE: ABT) shares declined following the release of Jensen Investment Management's second-quarter 2026 investor letter. The asset management firm, which returned 10.94% in Q2 2026, noted that Abbott detracted from its portfolio performance during the quarter due to a stock price drop after first-quarter earnings and lowered full-year guidance.
Management reduced its outlook primarily to account for dilution resulting from the Exact Sciences acquisition. Additionally, specific business segments, including Nutrition and portions of Diagnostics, faced near-term headwinds that impacted overall growth prospects despite strong underlying performance in other areas.
The stock also experienced pressure from ongoing legal uncertainty surrounding litigation related to preterm infant formula (NEC). These combined factors overshadowed otherwise robust results, specifically high-single-digit organic growth recorded in the Medical Devices and Established Pharma segments, which collectively account for over 62% of Q1 sales.
Jensen Investment Management currently does not rank Abbott among its top AI or monopoly stock picks, citing a belief that certain artificial intelligence stocks offer higher return potential within shorter timeframes. The fund holds 73 hedge fund portfolios in Abbott as of the end of the first quarter, down slightly from the previous quarter's count of 71.
📉 Abbott shares fell after Jensen highlighted guidance cuts and litigation risks.
📊 Full-year guidance lowered due to share dilution from Exact Sciences acquisition.
⚠️ NEC litigation over preterm infant formula continues weighing on investor sentiment.
📈 Medical Devices and Pharma segments delivered high-single-digit organic growth in Q1.
📉 Stock lost 18.43% over 52 weeks despite recent one-month gains.
📉 Abbott Laboratories (ABT) shares fell after Jensen Investment Management highlighted guidance cuts and litigation concerns overshadowing growth.
📊 The company lowered full-year guidance to reflect share dilution from the Exact Sciences acquisition.
⚠️ Ongoing uncertainty regarding NEC litigation over preterm infant formula continues to weigh on investor sentiment.
📈 Medical Devices and Established Pharma segments delivered high-single-digit organic growth, representing over 62% of Q1 sales.
🏥 Nutrition and portions of the Diagnostics business faced near-term headwinds impacting overall performance.
📉 Jensen Quality Growth Equity Strategy returned 10.94% in Q2 2026, trailing the S&P 500's 15.20% gain.
🔍 Abbott is not currently on Jensen's list of top AI or monopoly stocks for higher return potential.
📉 Hedge fund holdings in Abbott decreased slightly to 73 portfolios at the end of Q1 2026 from 71 previously.
💰 Abbott closed at $103.06 per share on July 24, 2026, with a market cap of approximately $179.51 billion.
📉 The stock lost 18.43% over the past 52 weeks despite a one-month return of 7.04%.
Bullish Signals
Medical Devices and Pharma drove high-single-digit organic growth.
Over 62% of Q1 sales came from these segments.
Market cap stands at approximately $179.51 billion.
Stock trades between $81.97 and $137.49.
Risk Factors
Guidance lowered due to Exact Sciences acquisition dilution.
Nutrition and Diagnostics segments face near-term headwinds.
NEC litigation uncertainty weighs on investor sentiment.
Stock price declined after Q1 earnings.
Bullish Signals
Medical Devices and Established Pharma segments achieved high-single-digit organic growth, driving revenue in areas representing over 62% of Q1 sales.
The company maintains a substantial market capitalization of approximately $179.51 billion with a trading range between $81.97 and $137.49.
Risk Factors
Management lowered full-year guidance to reflect dilution from the Exact Sciences acquisition.
Select businesses, including Nutrition and portions of Diagnostics, experienced near-term headwinds.
Ongoing uncertainty surrounding NEC litigation related to preterm infant formula continues to weigh on investor sentiment.
The stock price declined following Q1 earnings, detracting from Jensen Investment Management's portfolio performance.
Bank of Nova Scotia reduced its position in Abbott Laboratories (NYSE:ABT) by 16.8% in the first quarter, selling 52,490 shares to hold a remaining stake valued at $26.67 million. Conversely, several other institutional investors increased their holdings during the fourth quarter, including Freemont Management S.A., which grew its stake by 197.2%, and PFA Pension Forsikringsaktieselskab, which purchased a new position worth approximately $116.58 million.
Analyst sentiment regarding Abbott Laboratories remains mixed with varying price targets. Mizuho and Argus lowered their price targets to $115 and $125 respectively, while JPMorgan Chase raised its target to $120 with an overweight rating. Piper Sandler also increased its objective to $118. The consensus average target price stands at $118.61, supported by a majority of analysts maintaining Buy or Overweight ratings.
Abbott Laboratories reported a quarterly dividend of $0.63 per share payable on August 17th for shareholders of record on July 15th, yielding 2.4%. The company maintains a market capitalization of $179.63 billion and a P/E ratio of 33.38. Director Daniel J. Starks also acquired 10,000 shares in April, increasing his total ownership to over 6.75 million shares valued at roughly $625 million.
📉 Bank of Nova Scotia sold 52,490 shares, retaining $26.67 million stake.
📈 Freemont Management increased holding by 197.2% to own 10,700 shares.
💰 PFA Pension established new $116.58 million stake in Abbott Laboratories.
📊 JPMorgan raised price target to $120 with overweight rating on July 17.
💵 Abbott declared quarterly dividend of $0.63 per share, ex-date July 15.
📉 Bank of Nova Scotia trimmed its Abbott Laboratories position by 16.8% in Q1, selling 52,490 shares while retaining a stake worth $26.67 million.
📈 Freemont Management S.A. significantly increased its holding by 197.2% in Q4 to own 10,700 shares valued at $1.34 million.
💰 PFA Pension Forsikringsaktieselskab established a new stake in Abbott Laboratories worth approximately $116.58 million during the fourth quarter.
📊 JPMorgan Chase raised its price target for ABT from $110 to $120 and reaffirmed an overweight rating on July 17th.
📉 Mizuho decreased its price target from $125 to $115 and set a neutral rating in a report dated April 17th.
💵 Abbott Laboratories declared a quarterly dividend of $0.63 per share with an ex-dividend date of July 15th.
👔 Director Daniel J. Starks purchased 10,000 shares at an average cost of $92.65 in April, increasing his total ownership to over 6.75 million shares.
📈 The company currently trades with a market cap of $179.63 billion and a P/E ratio of 33.38.
🏥 Abbott operates globally through diagnostics, medical devices, nutritionals, and established pharmaceuticals segments.
Bullish Signals
Multiple institutional investors increased stakes in Q4.
Director acquired 10,000 shares signaling confidence.
JPMorgan raised target to $120; Piper Sandler to $118.
Strong balance sheet: debt-to-equity 0.56, current ratio 1.39.
Risk Factors
Mizuho lowered target to $115 with neutral rating.
Argus cut target from $140 to $125.
High 81.55% dividend payout limits capital flexibility.
Bullish Signals
Multiple institutional investors increased their stakes in the fourth quarter, including Freemont Management S.A., PFA Pension Forsikringsaktieselskab, Thrivent Financial, and Mn Services Vermogensbeheer B.V.
Director Daniel J. Starks acquired an additional 10,000 shares of common stock, signaling continued insider confidence in the company's long-term prospects.
JPMorgan Chase increased its price target to $120 and Piper Sandler raised its objective to $118, indicating bullish sentiment from major financial institutions.
The company maintains a strong balance sheet with a debt-to-equity ratio of 0.56 and a current ratio of 1.39.
Risk Factors
Mizuho lowered its price target to $115 and assigned a neutral rating, suggesting potential concerns about near-term performance or valuation.
Argus reduced its price target from $140 to $125, indicating a bearish shift in expectations for the stock's upside potential.
The dividend payout ratio is high at 81.55%, which may limit flexibility for future capital expenditures or share buybacks if earnings growth slows.
Arrowstreet Capital Limited Partnership significantly increased its stake in Abbott Laboratories (NYSE:ABT) by 217.0% in the first quarter, purchasing an additional 3.78 million shares to hold a total position of 5.52 million shares valued at $566.97 million. Several other institutional investors, including Caxton Associates, Dickmeyer Boyce, Ascension Capital, Forefront Analytics, and B&D White Capital, also established or increased their positions in the healthcare giant during the same period.
Analyst sentiment remains mixed but generally positive regarding Abbott's long-term prospects despite recent price target reductions. Major firms like Goldman Sachs, Barclays, Bank of America, UBS, and Leerink Partners lowered their price targets to $113, $143, $102, $135, and $106 respectively in April and June. However, the consensus rating remains a 'Moderate Buy' with an average price target of $118.61, supported by three Strong Buy ratings and nineteen Buy ratings from analysts.
Abbott Laboratories reported strong financial performance for the quarter ended July 16th, beating earnings estimates with $1.31 EPS against a consensus of $1.28. Revenue reached $12.51 billion, slightly missing expectations at $12.52 billion but growing 13.0% year-over-year. The company provided guidance for Q3 2026 EPS between $1.38 and $1.46 and full-year 2026 EPS between $5.45 and $5.60, while also announcing a quarterly dividend of $0.63 payable on August 17th.
📈 Arrowstreet Capital boosted Abbott stake by 217% to 5.52M shares worth $566.97M.
💰 Q2 EPS beat estimates at $1.31 with revenue growing 13% to $12.51B.
🔮 Full-year 2026 guidance set between $5.45 and $5.60 per share.
💵 Quarterly dividend of $0.63 offers a 2.5% annualized yield.
📉 Goldman Sachs cut price target to $113 while UBS lowered it to $135.
📈 Arrowstreet Capital boosted its Abbott Laboratories stake by 217.0% in Q1, adding 3.78 million shares to a total holding of 5.52 million shares worth $566.97 million.
🏦 Multiple institutional investors including Caxton Associates ($290k), Dickmeyer Boyce ($829k), Ascension Capital ($459k), and B&D White Capital ($2.41M) initiated new positions in the first quarter.
📉 Goldman Sachs lowered its price target to $113 with a 'buy' rating, while Bank of America cut its target to $102, reflecting cautious near-term outlooks from major banks.
📈 UBS Group reduced its price target to $135 but maintained a 'buy' rating, and Leerink Partners lowered its target to $106 with a 'market perform' rating.
💰 Abbott Laboratories reported Q2 EPS of $1.31, beating the consensus estimate of $1.28, while revenue grew 13.0% year-over-year to $12.51 billion.
📊 The company achieved a return on equity of 17.65% and a net margin of 11.65%, demonstrating solid profitability despite the slight miss in revenue expectations.
🔮 Abbott Laboratories issued Q3 2026 EPS guidance of $1.38-$1.46 and full-year 2026 guidance of $5.45-$5.60, with analysts expecting $5.51 EPS for the current fiscal year.
💵 The firm declared a quarterly dividend of $0.63 per share payable on August 17th to shareholders of record as of July 15th, representing a 2.5% annualized yield.
👔 Director Daniel J. Starks purchased 10,000 shares at an average price of $92.65, increasing his personal ownership by 0.15% to a total value of approximately $625.49 million.
📉 The stock trades at a P/E ratio of 32.64 with a market capitalization of $175.70 billion, currently trading above its 50-day moving average but below its 200-day average.
Bullish Signals
Arrowstreet Capital increased position by 217.0% in Q1.
Beat earnings with $1.31 EPS vs $1.28 consensus.
Revenue grew 13.0% year-over-year to $12.51 billion.
Healthy ROE of 17.65% and net margin of 11.65%.
Analysts rate Moderate Buy with $118.61 price target.
Strong balance sheet: debt-to-equity 0.56, current ratio 1.39.
Attractive 2.5% dividend yield with 81.55% payout ratio.
Risk Factors
Major analysts including Goldman Sachs lowered price targets.
Revenue of $12.51B missed expectations of $12.52B.
Stock trades below 200-day moving average of $101.32.
Full-year 2026 EPS consensus of $5.51 exceeds guidance.
Bullish Signals
Arrowstreet Capital increased its position by 217.0% in Q1, signaling strong institutional confidence in the company's long-term value.
Abbott Laboratories beat quarterly earnings estimates with $1.31 EPS compared to the consensus of $1.28.
Revenue grew 13.0% year-over-year to $12.51 billion, indicating robust top-line growth despite a slight miss in absolute revenue expectations.
The company maintains a healthy return on equity of 17.65% and a net margin of 11.65%, reflecting efficient operations.
Analysts maintain a 'Moderate Buy' consensus rating with an average price target of $118.61, supported by multiple 'Buy' and 'Strong Buy' ratings.
The company has a strong balance sheet with a debt-to-equity ratio of 0.56 and a current ratio of 1.39.
Abbott Laboratories offers an attractive dividend yield of 2.5% with a payout ratio of 81.55%, providing income to investors.
Risk Factors
Several major analysts, including Goldman Sachs, Bank of America, and UBS, recently lowered their price targets on Abbott Laboratories stock.
Revenue of $12.51 billion missed analyst expectations of $12.52 billion, indicating a slight slowdown in top-line growth.
The stock is trading below its 200-day simple moving average of $101.32, suggesting some short-term weakness or consolidation.
Analyst consensus for full-year 2026 EPS of $5.51 is slightly higher than the company's own guidance range of $5.45-$5.60, implying potential pressure to meet high expectations.
Abbott Laboratories (NYSE:ABT) saw significant institutional activity in the first quarter, with B&D White Capital Company LLC acquiring a new stake of 23,500 shares valued at approximately $2.41 million. Several other smaller funds also initiated positions in the fourth quarter, while hedge fund ownership remains high at 75.18%. Director Daniel J. Starks increased his personal holdings by purchasing 10,000 shares for roughly $926,500, bringing his total direct ownership to over 6.75 million shares.
Analyst sentiment regarding Abbott Laboratories is mixed but generally positive, with a consensus rating of 'Moderate Buy' and an average price target of $118.61. While Goldman Sachs, Stifel Nicolaus, and Evercore recently lowered their price targets to the $113-$120 range, JPMorgan Chase and BTIG Research raised theirs to $120 and $134 respectively. The stock currently trades around $100.69, trading below its 200-day moving average but above its 50-day average.
Financially, Abbott reported strong quarterly results with revenue of $12.51 billion, slightly missing estimates by a negligible margin, and earnings per share (EPS) of $1.31, which beat the consensus of $1.28. The company posted a 13% year-over-year revenue increase, maintaining healthy margins of 11.65% and a return on equity of 17.65%. Management has provided guidance for Q3 2026 EPS between $1.38 and $1.46, with full-year 2026 targets ranging from $5.45 to $5.60.
📈 B&D White Capital acquired 23,500 Abbott shares worth $2.41 million in Q1.
📊 EPS reached $1.31, beating estimates by $0.03 with strong 2026 guidance.
👔 Director Daniel Starks bought 10,000 shares at an average cost of $92.65.
💵 Quarterly dividend declared at $0.63 per share payable on August 17th.
📈 B&D White Capital Company LLC acquired a new stake of 23,500 shares in Abbott Laboratories valued at approximately $2.41 million during the first quarter.
📉 Goldman Sachs lowered its price target to $113.00 while maintaining a 'buy' rating, and Stifel Nicolaus reduced its target to $120.00 with a 'buy' rating.
📈 JPMorgan Chase increased its price target to $120.00 and assigned an 'overweight' rating in a July 17th research note.
💰 Abbott Laboratories reported quarterly revenue of $12.51 billion, representing a 13% year-over-year increase compared to the prior period.
📊 The company posted earnings per share of $1.31 for the quarter, topping analyst estimates of $1.28 by $0.03.
📅 Abbott Laboratories set Q3 2026 EPS guidance between $1.38 and $1.46, with full-year 2026 guidance ranging from $5.45 to $5.60.
💵 The firm declared a quarterly dividend of $0.63 per share payable on August 17th for stockholders of record on July 15th.
👔 Director Daniel J. Starks purchased 10,000 shares at an average cost of $92.65, increasing his direct ownership by 0.15%.
📉 The stock opened at $100.69 with a market capitalization of $175.38 billion and a P/E ratio of 32.59.
🏥 Abbott operates through diagnostics, medical devices, nutritionals, and pharmaceuticals, serving hospitals, clinics, and direct-to-consumer channels.
Bullish Signals
Beat EPS expectations at $1.31 vs $1.28 consensus.
Revenue surged 13% YoY to $12.51 billion.
JPMorgan upgraded to 'overweight' with $120 price target.
Healthy balance sheet: debt-to-equity 0.56, current ratio 1.39.
Strong 2.5% dividend yield with $2.52 annual payout.
Risk Factors
Goldman Sachs lowered price target from $121.00 to $113.00.
Stifel Nicolaus decreased price target from $145.00 to $120.00.
Stock trades below 200-day moving average of $101.48.
Consensus EPS of $5.51 slightly exceeds management guidance.
Bullish Signals
Abbott Laboratories beat quarterly earnings expectations with EPS of $1.31 versus the consensus estimate of $1.28.
The company achieved a 13% year-over-year revenue increase to $12.51 billion, demonstrating strong top-line growth.
JPMorgan Chase raised its price target to $120.00 and upgraded the rating to 'overweight', signaling confidence in future performance.
The firm maintains a healthy balance sheet with a debt-to-equity ratio of 0.56 and a current ratio of 1.39.
Abbott Laboratories has a strong dividend yield of 2.5% with an annualized payout of $2.52 per share.
Management provided clear forward guidance for Q3 2026 EPS between $1.38 and $1.46, indicating operational stability.
Risk Factors
Goldman Sachs lowered its price target from $121.00 to $113.00, reflecting a more cautious near-term outlook.
Stifel Nicolaus decreased its price target from $145.00 to $120.00, suggesting potential headwinds or valuation concerns.
The stock is trading below its 200-day moving average of $101.48, indicating some short-term weakness relative to longer-term trends.
Equities research analysts predict a consensus EPS of $5.51 for the current year, which is slightly higher than management's upper guidance range of $5.60, implying potential pressure on expectations.
Your Privacy
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Measure audience engagement and site statistics to understand how our services are used (Google Analytics)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
You can accept all cookies or configure your preferences. You can change them at any time via the "Manage Cookies" link in the footer.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Analytics cookies
Help us understand how visitors interact with our website using Google Analytics. These cookies collect information anonymously.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
